Chinese licensing deal for PD-L1 drug in hep B

14 January 2019

Chinese companies Ascletis Pharma (HKG: 1672) and Suzhou Alphamab have signed a strategic collaboration and exclusive licensing agreement for the anti-PD-L1 drug KN035, to treat hepatitis B and other viral diseases in China.

KN035 has been exposed to more than 500 patients in multiple clinical trials in the USA, China and Japan.

Under the terms of the agreement, Ascletis has an exclusive license from Alphamab to develop and commercialize KN035 for viral diseases including hepatitis B in Greater China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK